The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …

A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Under the auspices of an International Working Group, seven centers submitted diagnostic
and follow-up information on 1545 patients with World Health Organization-defined …

Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform
for prospective studies exploring preventive measures. Current risk stratification for …

Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by
arterial and venous complications, progression to myelofibrosis, and transformation to acute …

High platelet counts in essential thrombocythemia (ET) can be effectively lowered by
treatment with either anagrelide or hydroxyurea. In 259 previously untreated, high-risk …

In the last years, a growing amount of evidence has been produced regarding the role of
leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms …

Abstract Background Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms
(MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most …

Practical and clinically focused, Abeloff's Clinical Oncology is a trusted medical reference
book designed to capture the latest scientific discoveries and their implications for cancer …

Essential thrombocythemia (ET) is characterized by enhanced platelet generation and
thrombotic complications. Once-daily low-dose aspirin incompletely inhibits platelet …